CSBio CSBio

X
[{"orgOrder":0,"company":"Dualogics","sponsor":"AbCellera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera Acquires OrthoMab Bispecific Platform to Propel the Development of Antibody Therapies for Pharma and Biotech Partners","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"INDIA","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Dualogics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the terms of the asset purchase agreement, AbCellera acquires full rights to the OrthoMab platform and Dualogics retains rights to develop existing internal assets and to complete existing partnership programs.

            Lead Product(s): IgG-like bispecific antibodies

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: AbCellera

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition August 20, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY